Beta talasemi majör hastalarında deferoksamin ve deferosiroks bazı immünolojik yanıtlar, biyokimyasal, hormonal ve hematolojik özellikler üzerine etkisi

Thalassemia is a genetic blood disease known by an abnormally low hemoglobin ratio, leading to severe anemia in both genders. It is classified into alpha and beta thalassemia. Frequent blood transfusions are essential for survival but can lead to excess iron. Chelating therapies, such as deferasirox, and deferoxamine are used to manage iron overload in patients with BTM. This study was conducted at Azadi Teaching Hospital's Thalassemia Centre, involving 200 patients with beta thalassemia major over 18 years old. The patients were divided into two categories: transfusion-dependent patients who were prescribed deferasirox or deferoxamine as iron chelators. The control group included 100 healthy individuals (patients without thalassemia disease) was also included. Statistical analysis (ANOVA, Kruskal-Wallis, Pearson correlation coefficient) revealed that deferoxamine was more beneficial than deferasirox in improving levels of HCT, RBC, MCH, Hb, GH, EBC, lymphocytes, creatinine, TSH, prolactin (in both males and females), and TLR3. In contrast, deferasirox was more effective in reducing platelet count, ferritin, iron, calcium, AST, ALT, ALP, GGT, LH, FSH (in both males and females), and IL6 and IL8. Furthermore, Deferasirox was more effective in reducing iron overload in the thyroid gland and had a more comprehensive impact on iron levels throughout the body, which made it safer for use due to its extended half-life. When we evaluate the results in general, we can say that deferasirox is more effective and safer than deferoxamine.